PET and PET/CT in pediatric oncology

被引:80
作者
Jadvar, Hossein
Connolly, Leonard P.
Fahey, Frederic H.
Shulkin, Barry L.
机构
[1] St Jude Childrens Res Hosp, Div Diagnost Imaging, Memphis, TN 38105 USA
[2] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Nucl Med, Boston, MA 02115 USA
[3] Univ So Calif, Keck Sch Med, Dept Radiol, Div Nucl Med, Los Angeles, CA USA
关键词
D O I
10.1053/j.semnuclmed.2007.04.001
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) and FDG-PET/computed tomography (CT) are becoming increasingly important imaging tools in the noninvasive evaluation and monitoring of children with known or suspected malignant diseases. In this review, we discuss the preparation of children undergoing PET studies and review radiation dosimetry and its implications for family and caregivers. We review the normal distribution of 18F-fluorodeoxyglucose (FDG) in children, common variations of the normal distribution, and various artifacts that may arise. We show that most tumors in children accumulate and retain FDG, allowing high-quality images of their distribution and pathophysiology. We explore the use of FDG-PET in the study of children with the more common malignancies, such as brain neoplasms and lymphomas, and the less-common tumors, including neuroblastomas, bone and soft-tissue sarcomas, Wilms' tumors, and hepatoblastomas. For comparison, other PET tracers are included because they have been applied in pediatric oncology. Multiple multicenter trials are underway that use FDG-PET in the management of children with neoplastic disease; these studies should give us greater insight into the impact FDG-PET can make in their care. PET is emerging as an important diagnostic imaging tool in the evaluation of pediatric cancers. The recent advent of dual-modality PET-computed tomography (PET/CT) imaging systems has added unprecedented diagnostic capability by revealing the precise anatomical localization of metabolic information and metabolic characterization of normal and abnormal structures. The use of CT transmission scanning for attenuation correction has shortened the total acquisition time, which is an especially desirable attribute in pediatric imaging. Moreover, expansion of the regional distribution of the most common PET radiotracer, FDG, and the introduction of mobile PET units have greatly increased access to this powerful diagnostic imaging technology. Here, we review the clinical applications of PET and PET/CT in pediatric oncology. General considerations in patient preparation and radiation dosimetry will be discussed.
引用
收藏
页码:316 / 331
页数:16
相关论文
共 189 条
[1]   The role of nuclear medicine in primary bone and soft tissue tumors [J].
AbdelDayem, HM .
SEMINARS IN NUCLEAR MEDICINE, 1997, 27 (04) :355-363
[2]   Colonic neuroendocrine carcinoma in a child [J].
Al Sasi, O ;
Sathiapalan, R ;
Rifai, A ;
Tulbah, AMM ;
Al-Mehaidib, A ;
Kofide, A ;
Hugosson, C .
PEDIATRIC RADIOLOGY, 2005, 35 (03) :339-343
[3]  
*AM SOC AN, ANESTHESIOLOGY, V96, P1004
[4]   FDG-PET in 10 children with non-Hodgkin's lymphoma:: Initial experience in staging and follow-up [J].
Amthauer, H ;
Furth, C ;
Denecke, T ;
Hundsdoerfer, P ;
Voelker, T ;
Seeger, K ;
Stöver, B ;
Henze, G .
KLINISCHE PADIATRIE, 2005, 217 (06) :327-333
[5]   Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDC-PET) for accurate staging of Hodgkin's disease [J].
Bangerter, M ;
Moog, F ;
Buchmann, I ;
Kotzerke, J ;
Griesshammer, M ;
Hafner, M ;
Elsner, K ;
Frickhofen, N ;
Reske, SN ;
Bergmann, L .
ANNALS OF ONCOLOGY, 1998, 9 (10) :1117-1122
[6]   The incremental value of 18F-FDG PET/CT in paediatric malignancies [J].
Bar-Sever, Zvi ;
Keidar, Zohar ;
Ben-Barak, Ayelet ;
Bar-Shalom, Rachel ;
Postovsky, Sergey ;
Guralnik, Luda ;
Ben Arush, Myriam W. ;
Israel, Ora .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (05) :630-637
[7]  
BARNEWOLT CE, 1997, GENITOURINARY SYSTEM, P1009
[8]  
Barrington S F, 1995, Clin Oncol (R Coll Radiol), V7, P334, DOI 10.1016/S0936-6555(05)80549-7
[9]  
BarSever Z, 1997, J NUCL MED, V38, P42
[10]  
Ben Arush MW, 2001, PEDIATR HEMAT ONCOL, V18, P295